Drug Trial Radar · NCT06035497
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
83
Planned (sponsor's estimate)
Start
Nov 20, 2023
Primary completion
Aug 11, 2026
Study completion Oct 10, 2030
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Sep 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).
Conditions
- Relapsed or Refractory T-cell Lymphomas
Interventions
BMS-986369Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events (AEs)Time frame: Up to 5 weeks after last dose of treatment
- Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Up to 5 weeks after last dose of treatment
- Number of participants with Dose-Limiting Toxicity (DLT)Time frame: Up to 28 days after first dose
- Number of participants with laboratory abnormalitiesTime frame: Up to 5 weeks after last dose of treatment
- Number of participants with vital sign abnormalitiesTime frame: Up to 5 weeks after last dose of treatment
- Number of participants with Electrocardiogram (ECG) abnormalitiesTime frame: Up to 5 weeks after last dose of treatment
- Eastern Cooperative Oncology Group Performance Status (ECOG PS)Time frame: Up to 5 weeks after last dose of treatment
- Number of participants with Left Ventricular Ejection Fraction (LVEF) assessment abnormalitiesTime frame: Up to 5 weeks after last dose of treatment
- Number of participants with Physical Examination (PE) abnormalitiesTime frame: Up to 5 weeks after last dose of treatment
- Number of participants who achieve Objective Response (OR) as assessed by central review per international consensus response criteria for ATLTime frame: Up to 2 years after last does of treatment
- Number of participants who achieve OR as assessed by central review per protocol-defined response criteria according to Lugano classification (Computed Tomography(CT)-based)Time frame: Up to 2 years after last dose of treatment
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
Local Institution - 0018
Fukuoka, Japan
Local Institution - 0012
Fukuoka, Japan
Local Institution - 0023
Fukuoka, Japan
Local Institution - 0039
Hiroshima, Japan
Local Institution - 0025
Hiroshima, Japan
Local Institution - 0015
Kagoshima, Japan
Local Institution - 0008
Kagoshima, Japan
Local Institution - 0035
Kumamoto, Japan
Local Institution - 0006
Kumamoto, Japan
Local Institution - 0027
Kyoto, Japan
Local Institution - 0022
Mitaka, Japan
Local Institution - 0038
Miyazaki, Japan
Local Institution - 0030
Nagasaki, Japan
Local Institution - 0020
Ōita, Japan
Local Institution - 0007
Okayama, Japan
Local Institution - 0042
Okinawa, Japan
Local Institution - 0010
Osaka, Japan
Local Institution - 0034
Osaka, Japan
Local Institution - 0031
Anjo-shi, Aichi-ken, Japan
Local Institution - 0011
Nagoya, Aichi-ken, Japan
Local Institution - 0024
Toyohashi, Aichi-ken, Japan
Local Institution - 0017
Kamogawa, Chiba, Japan
Local Institution - 0002
Kashiwa, Chiba, Japan
Local Institution - 0037
Narita, Chiba, Japan
Local Institution - 0016
Iizuka, Fukuoka, Japan
Local Institution - 0041
Kitakyushu-shi, Fukuoka, Japan
Local Institution - 0036
Sapporo, Hokkaido, Japan
Local Institution - 0032
Amagasaki, Hyōgo, Japan
Local Institution - 0033
Kobe, Hyōgo, Japan
Local Institution - 0004
Isehara, Kanagawa, Japan
Local Institution - 0013
Yokosuka, Kanagawa, Japan
Local Institution - 0001
Sendai, Miyagi, Japan
Local Institution - 0019
Ōmura, Nagasaki, Japan
Local Institution - 0028
Sasebo, Nagasaki, Japan
Local Institution - 0005
Ōsaka-sayama, Osaka, Japan
Local Institution - 0009
Hidaka, Saitama, Japan
Local Institution - 0003
Chuo-ku, Tokyo, Japan
Local Institution - 0040
Koto, Tokyo, Japan
Local Institution - 0026
Minato-ku, Tokyo, Japan
Local Institution - 0029
tabashi City, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.